TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,028,613 | +63.2% | 2,240,337 | +180.5% | 0.00% | +100.0% |
| Q2 2023 | $12,269,246 | -39.0% | 798,779 | -10.6% | 0.00% | -50.0% |
| Q1 2023 | $20,103,137 | +38.1% | 893,870 | +29.1% | 0.00% | 0.0% |
| Q4 2022 | $14,557,050 | +58.4% | 692,204 | +85.5% | 0.00% | +100.0% |
| Q3 2022 | $9,192,000 | -35.2% | 373,068 | -36.3% | 0.00% | -50.0% |
| Q2 2022 | $14,192,000 | +13.3% | 585,773 | +20.5% | 0.00% | 0.0% |
| Q1 2022 | $12,522,000 | +29.4% | 485,942 | +55.8% | 0.00% | +100.0% |
| Q4 2021 | $9,679,000 | +4.8% | 311,807 | -18.1% | 0.00% | 0.0% |
| Q3 2021 | $9,237,000 | +361.6% | 380,935 | +177.9% | 0.00% | – |
| Q2 2021 | $2,001,000 | +204.6% | 137,083 | +419.8% | 0.00% | – |
| Q1 2021 | $657,000 | -59.9% | 26,373 | -56.1% | 0.00% | – |
| Q4 2020 | $1,637,000 | – | 60,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |